TSPO and cognitive disorder: On the other hand, this result might indicate that this binding of 18F-DPA-714, biomarker of TSPO, in the temporal lobe at the early stages of the disease was an early marker of cognitive disorders probably preceding the occurrence of neuropsychological impairment, considered to affect 10 to 50% of ALS patients [33].